Jun. 23 at 1:03 AM
$GRAL just made news on NPR for its Galleri test pending FDA approval at the close of the year. GRAL has a market cap of
$2.7B. While the Galleri test is pioneering liquid biopsy technology, it is relatively expensive
$1000, long-lead and limited to specialized technical labs. Contrast that with
$VNRX CaptureSeq which shows comparable specificity, but outstanding detection of Phs-1/2 cancers at a fraction of the cost using technology at nearly any/all hospitals worldwide. IP secured to 2044 and market cap of
$12M, grossly Oversold and in discussions with all leading liquidity biopsy/diagnostic Companies globally on licensing agreements.
https://www.npr.org/2026/06/21/nx-s1-5858691/blood-test-multi-cancer-early-detection-mced
